Astrazeneca Ab

Nps Pharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc.

David Wensbo

Abdelmalik Slassi

Louise G Edwards

Methvin Benjamin Isaac

Tao Xin

Jalaj Arora

Tomislav Stefanac

Alexander Minidis

Martin Johansson

Annika Kers

Daniel Sohn

Donald A McLeod

Can Slivo

Jonas Malmstrom

Karin Staaf

David Pyring

Gunnar Nordvall

Britt-Marie Swahn

Thomas M Stormann

Ylva Gravenfors

Catrin Jonasson

Peter Strom

Anne O'Brien

Erwan Arzel

Ulrika Yngve

Helena Gyback

Christoffer Osterwall

Mangus Waldman

Karin Oscarsson

John Malmberg

Tom Stefanac

Per-Olov Bergstrom

Veronica Profir

Caroline Eriksson

Don McLeod

Tau Xin

Alexander Mindis

Johan Malmberg

Donald Mcleod

Thomas Stormann

The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Heteroaryl substituted benzothiazoles

The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. 

The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

2-heteroaryl substituted benzothiophenes and benzofuranes 709

The present invention relates to new compounds of formula I, wherein P, Q, X, X, X, X, R, R, m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Tetrazole compounds and their use as metabotropic glutamate receptor antagonists

The present invention relates to novel heteroaryl substituted benzoxazole derivatives and therapeutic uses for such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzoxazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Heteroaryl substituted benzoxazoles

The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention is directed to compounds of formula I: wherein X, X, X, X, X, X, X, X, X, X, R, R, R, R, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.

Compounds for the treatment of neurological, psychiatric or pain disorders

The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.

Compounds

The present invention relates to new compounds of formula I, wherein P, Q, X, X, X, X, X, R, R, R, R, R, R, G, M, M, M, m and n, are defined as in formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

Growing community of inventors

Södertälje, Sweden

David Wensbo